

## Potential Neurological Outcomes in COVID-19 Patients: A Review

Abhishek Lal, Mahnoor Khawaja M. Saleem, Yousuf Ali Lakdawala

### ABSTRACT:

Coronavirus emerged from Wuhan China, which has been a global challenge for healthcare authorities and individuals. Patients are presenting to the clinicians with neurological symptoms caused by COVID-19 or with preexisting neurological conditions with fear of contracting the virus. We have conducted a literature review on neurological outcomes in COVID-19 patients along with patients with underlying neurological conditions. We searched multiple databases including PubMed, Google Scholar, EBSCO, Semantic Scholar, and Wiley Online for information on neurological manifestations of patients suffering from coronavirus. Clinical data and co-morbidities of the patients were examined. Headache, dizziness, hyposmia, and stroke were among the symptoms reported. Emerging literature is suggesting that coronavirus patients along with respiratory symptoms are also experiencing neurological symptoms. Some medical emergencies such as stroke require immediate treatment to save the patients. Neurologists and clinicians need to recognize these symptoms in order to timely manage and treat the patients.

**Keywords:** Coronavirus, Manifestations, Neurology

### How to cite this Article:

Lal A, Saleem MKM, Lakdawala YA. Potential Neurological Outcomes in COVID-19 Patients: A Review. J Bahria Uni Med Dental Coll. 2020; 10(4): 310-315 DOI: <https://doi.org/10.51985/JBUMDC2020059>

### INTRODUCTION:

From a market in the city of Wuhan, Hubei, China in December 2019 marked the beginning of Novel Coronavirus which was identified from unknown cases of pneumonia.<sup>1</sup> Initially, the viral infection was disseminating in China, leading them to impose precautionary measures to contain and control the virus. However, the virus then started to transmit outside China, and as of now, has engulfed almost all of the countries. Keeping this in mind, on 11<sup>th</sup> March 2020, the World Health Organisation declared novel coronavirus as a pandemic and guided world health community information on necessary precautionary measures.<sup>2</sup> Additionally, with the rapid dissemination of this pathology, individuals as well as healthcare authorities came under immense pressure and stressed on control and protect oneself and the community. Many studies have suggested that the possible origin of coronavirus is from bats, the virus was transmitted from these bats and then infected mammals.<sup>3</sup> Coronavirus is suggested to infect many organ systems of the body including the central nervous system (CNS), hepatic, cardiovascular, and respiratory.<sup>4</sup> Primary physical effects of

Novel coronavirus has been on the respiratory system, but nervous system outcomes have also been seen in patients.<sup>5</sup>

Primarily, the mode of transmission for coronavirus has been through respiratory droplets by a close and direct human to human contact.<sup>6</sup> Furthermore, clinical features of the infected person include fever, dry cough, sore throat, and myalgia, although some patients may also experience neurological and stomach upset symptoms.<sup>7</sup> On one hand, individuals particularly elderly and with underlying co-morbidities are more prone to develop a severe infection as well as mortalities from it.<sup>8</sup> On the other hand, young individuals without any co-morbidities are facing morbidities and mortalities from this virus.<sup>9</sup> A major hurdle in containing this virus is identifying those people who are infected but remain symptomless and are disseminating the pathology around them.

Coronavirus genome has 4 genera consisting of alpha, beta, gamma, and delta, being of single-stranded positive-sense RNA.<sup>10</sup> One of the key topics regarding coronavirus has been its pathogenesis. Previously, many studies have suggested the mode of action of coronavirus in the human body. SARS-CoV after entering the human body initiates its action by binding to Angiotensin-Converting Enzyme 2 (ACE2), which has been suggested to be its primary mode of action.<sup>10</sup> Additionally, SARS-CoV also uses protease TMPRSS2 for S protein priming. In human ACE2 receptor is expressed in tissues like airway epithelium, kidneys, lungs parenchyma, vascular endothelium, and central nervous system.

Some reports have emerged stating the potential of SARS-CoV to invade the central nervous system and mediate its actions.<sup>11</sup> Although damage by this virus has been reported

**Abhishek Lal**  
Student, Final Year  
Altamash Institute of Dental Medicine, Karachi  
Email: [abhishekdarshan@yahoo.com](mailto:abhishekdarshan@yahoo.com)

**Mahnoor Khawaja M. Saleem**  
Student, Final Year  
Altamash Institute of Dental Medicine, Karachi

**Yousuf Ali Lakdawala**  
Professor, Department of Surgery,  
Fazaiya Ruth Pfau Medical College, Karachi

Received: 29-Jul-2020  
Accepted: 03-Sep-2020

in COVID-19 patients with different symptoms arising in them, the extent to which damage occurs is yet to be discovered. Studying the effects of novel coronavirus to CNS can open doorways to patients suffering from their effects, helping in formulating effective treatment modalities.

**METHODOLOGY:**

For this literature review, we used multiple databases such as PubMed, Google Scholar, EBSCO, Semantic Scholar, and Wiley Online along with the snowballing technique. A large number of articles was found in these databases using the following generic terms such as “Coronavirus”, “COVID-19” and “Neurology”.

A total of 1508 articles were found. After a discussion with all the authors who performed the literature review, 177 number of articles were screened for relevancy. Articles that were collected were screened based on information extracted from their titles, abstracts, and full text of the articles. The extracted articles were screened by looking at the following information: a) Title, b) Authors, c) Abstract, d) Journal, e) Main text, f) Article type and g) Publication Date. Articles were included on the basis of being related to Coronavirus along with neurological association with it. The exclusion of the articles was mainly due to not being related to the respective literature, not being in English language and articles that were not published in a journal.

**Pathogenesis of SARS-CoV in CNS**

As it has been mentioned previously, SARS-CoV mainly mediates in action by binding to ACE2 receptors<sup>12</sup>. Central nervous system (CNS) has been found to have these receptors present, thereby, some infected individuals experiencing symptoms related to this organ system.<sup>13</sup> Although some studies do report that the mere presence of these receptors does not necessarily mean that virus is going to invade the particular organ system.<sup>14</sup> Previously, some studies have suggested that some patients with SARS only had the virus present exclusively in neurons.<sup>15</sup>

ACE2 receptors have also found to be present in glial cells and spinal neurons, where they can divide and multiply to damage the cells. Some studies have suggested that the primary mode by which coronavirus invades and damages the CNS is by the way of the olfactory bulb.<sup>16</sup> Through this route, the virus enters the olfactory bulb, and further damages other parts of the brain such as thalamus and brain stem. ACE2 receptors have also been strongly expressed in two areas of the brain responsible for the regulation of respiratory cycle, ventrolateral medulla, and nucleus of the tractus solitaries.<sup>17</sup> Prior studies have suggested that when SARS-CoV invades CNS, it induces direct neural death in the respiratory center of the medulla by upregulation of IL-1, IL-6, and TNF-alpha, thereby initiating inflammatory response.<sup>18</sup> Recently, an emerging hallmark of coronavirus has been coagulopathy, whereby “sepsis-induced coagulopathy” arises in patients being in hypercoagulation

state, predisposing to conditions such as stroke.<sup>19</sup>

**Neurological damage ensued by COVID-19**

Talking about mechanisms by which SARS-CoV causes neurological damage, the virus gains entry into cerebral circulation and sluggishly moves forward. Once within the neuronal tissues, interaction with the ACE2 receptors commences its action.<sup>13</sup> Additionally, because the virus gains entry through the purposed olfactory route, disturbance in smell sensation has been noted in a handful of patients.<sup>20</sup> Moreover, immunological damage to CNS is initiated by cytokine storm whereby novel coronavirus induces innate immune system in the host to release cytokines such as IL-1, IL-6, and TNF-alpha, so producing an inflammatory response which damages the neuronal tissues.<sup>21</sup> Furthermore, all this leads to brain hypoxia, causing further damage.<sup>22</sup> Lastly, pneumonia is caused by the coronavirus, which further aggravates hypoxic brain injury.

**Neurological Symptoms of COVID-19 Patients**

Literature has stated many potential symptoms experienced by coronavirus patients. COVID-19 patients have neurological symptoms such as headache, myalgia, confusion, and dizziness.<sup>23</sup> Moreover, some patients also experienced hyposmia and dysgeusia as well.<sup>24-26</sup> Mao et al reported that some patients also suffered from cerebrovascular diseases including ischemic stroke and cerebral hemorrhage.<sup>27</sup> Some common neurological manifestations of COVID-19 have been listed in Table 1.

**Central Nervous System Manifestations**

Location	Manifestations
Central Nervous System	Headache
	Dizziness
	Cerebrovascular Disease
	Epilepsy
	Encephalopathy
	Ataxia
Peripheral Nervous System	Hypogeusia
	Hyposmia
	Neuralgia

**1. Stroke:**

Stroke has occurred in some coronavirus patients, presenting as a medical emergency.<sup>28</sup> Furthermore, stroke has occurred in coronavirus patients in both young and old age groups.<sup>29</sup> The purposed mechanism that might predispose a person to stroke is by hypercoagulation associated with COVID-19 which induces a sepsis-induced coagulopathy.<sup>19</sup> A study reports that stroke was more commonly associated with COVID-19 patients suffering from a severe infection, which has further contributed in the mortality rates.<sup>30</sup> Additionally, it has been suggested that some individuals who contract

the virus may already have cerebrovascular risk factors such as hypertension, diabetes, hyperlipidemia, and previous history of stroke, predisposing them to stroke when infected with the novel coronavirus.<sup>30</sup> Abnormal laboratory investigations include elevated levels of leukocyte count, C-reactive protein, D-dimer and ferritin levels.<sup>31</sup>

## **2. Seizures:**

Many studies have reported incidents of seizures in patients suffering from coronavirus.<sup>32,33</sup> Initially, the COVID-19 patients presented only with usual symptoms, but later on developed complications such as seizures.<sup>34</sup>

## **3. Encephalitis:**

Initially, the first case of coronavirus patients who suffered from encephalitis was reported from Japan<sup>35</sup>. Physically this patient experienced neck stiffness with Brain CT scan being normal. The mechanism by which SARS-CoV might lead to encephalitis is by direct viral invasion, attachment to ACE2 receptors through the blood-brain barrier.<sup>33</sup> It can be postulated that those patients who suffer from severe coronavirus infection are especially predisposed to suffer from neurological complications.

## **4. Encephalopathy:**

Encephalopathy manifests in patients that suffer from severe COVID-19 infections.<sup>36</sup> Although, it has been suggested that disseminated intravascular coagulation and venous thromboembolism caused by this virus might cause encephalopathy.<sup>37</sup> An elderly patient suffering from COVID-19 has been reported to develop complications of encephalopathy.<sup>38</sup> From China, it has been reported that some patients also experienced hypoxic encephalopathy.<sup>39</sup> Furthermore, cases of acute necrotizing encephalopathy have also been reported in some patients, mechanism of which is mainly by cytokine storm causing a large amount of cytokine to be released and crossing the blood-brain barrier to cause injury.<sup>40</sup> Lastly, those individuals who have been suffering from encephalopathy may have been predisposed to stroke.<sup>41</sup>

## **5. Dizziness and Headache**

Dizziness and headache have been regarded as one of the most common neurological symptoms experienced by COVID-19 patients.<sup>27,42,43</sup> Furthermore, the release of cytokines and chemokines by the macrophages during coronavirus infection might be associated with headache.<sup>44</sup> Although the commonality of these symptoms has been clearly stated, the precise pathophysiology and mechanism are still to be figured out.

## **Peripheral Nervous System Manifestations:**

### **1. Anosmia and Hypogeusia:**

Many studies report that anosmia and hypogeusia are one of the common and first neurological manifestations in coronavirus patients, and may even occur before the

occurrence of respiratory symptoms.<sup>34,45</sup> In a study, nearly a quarter of the patient's sample reported experiencing anosmia, with improvement occurring after one week.<sup>46</sup> The virus primarily gains entry into the cerebral circulation by firstly passing through the olfactory bulb. This has been known to cause a disturbance in the smell sensation of the infected people. Studies further report that some patients might only experience disturbance in smell sensation and asked to self-isolate themselves.<sup>45</sup>

### **2. Skeletal Muscle Injury:**

Although less common, skeletal muscle injury has also been on the neurological symptoms experienced by the patients.<sup>47</sup> An elderly person in China, known case of coronavirus, after being admitted to hospital was found to have limb weakness after the neurological examination was performed.<sup>48</sup> Similarly as stated before, skeletal muscle injury is also one of that neurological symptom experienced by patients with severe infection.<sup>49</sup>

### **Special Care For Patients With Underlying Neurological Conditions**

Many patients, particularly those who are above 65 and with underlying medical conditions are more anxious and stressed to contract viruses and might suffer from severe infection. Mortality rates are keenly observed more in this age group. So, emphasis on special care and support for these patients is precisely required.

**Multiple Sclerosis:** Patients with multiple sclerosis are taking drugs that might predispose them to contract the virus more rapidly and suffer severe infection from it, as compared to a healthy individual. Currently, no consensus has been reached whether to modulate drug therapy for the patient and their susceptibility to contracting the virus.<sup>50</sup> Furthermore, no precise mechanism by which multiple sclerosis patients develop coronavirus infection is yet to be discerned.<sup>51</sup> Recently a study reported adamantanes being successfully used in patients and reported no change in their neurological functions.<sup>52</sup>

**Parkinson's Disease:** Due to the current situation, the clinical visits required by the Parkinson's Disease (PD) patients are suspended, which increases stress and confusion amongst them. It has been reported that some patients developed increased psychiatric symptoms such as hallucinations, anxiety, and psychosis.<sup>53</sup> Generally, patients have been inquiring about the COVID-19 pathology and their susceptibility to contracting the virus. Currently, no definitive association can be developed between the two pathologies.<sup>54</sup> Additionally, it has been suggested that Parkinson's patients with restricted lung capacity to axial akinesia are predisposed to develop coronavirus infection.<sup>55</sup> Lastly, the correlation between Parkinson's disease and coronavirus is currently unknown, but the subject matter has particularly generated stress among the sufferers of PD.<sup>56</sup>



**Epilepsy:** Epilepsy, being one of the common neurological disorders, is also highlighted here. Currently, the practice implemented is to keep epilepsy patients out of the hospitals due to the likelihood of contracting the virus and practicing home care.<sup>57</sup> Almost all of the drugs administered to the epileptic patients are not immunosuppressive so decreasing the chances of contracting the virus. Furthermore, it has been stated that patients with epilepsy are not more prone to contract the virus as well as suffering a severe infection from it.<sup>58</sup> Clinicians who are managing epileptic patients should guide their patients on which medications to take.<sup>59</sup>

**Neuromuscular Disorders:** Patients with neuromuscular disorders are currently on immunosuppressive drugs, increasing their likelihood of contracting the virus. Moreover, patients particularly suffering from Myasthenia Gravis and Lambert-Eaton Syndrome may have respiratory muscle weakness, which may predispose them to develop complications from the novel coronavirus if they contract it.<sup>60</sup> Those on immunosuppressive medicines should be extra-cautious and maintain social distancing more vigilantly.<sup>60</sup> Lastly, it has been stated that Hydroxychloroquine is known to exacerbate symptoms of myasthenia gravis and is, therefore, contraindicated in these patients.

#### CONCLUSION:

Currently, the entire global community is in grips of the novel coronavirus. However, understanding the neurological manifestations of coronavirus is being evolved rapidly, practitioners should look for these symptoms for timely management of the patients. Timely and early detection not only decreases morbidities but also promotes hassle-free recovery of the patients. Furthermore, additional knowledge on lab work, pathophysiology, and treatment options for these patients should be looked for so that better recovery of the patients can be expected. Knowledge of all these things will help neurologists, scientists, and clinicians to treat their patients optimally.

#### Author Contribution:

Abhishek Lal: Literature review, drafted the manuscript and formulated methodology  
 Mahnoor Khawaja M. Saleem: Literature review and drafted the manuscript  
 Yousuf Ali Lakdawala: Conducted the final revision of the manuscript

#### REFERENCES:

- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *Vol. 382, New England Journal of Medicine*. 2020. p. 1199–207.
- WHO. WHO declares pandemic [Internet]. Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>

- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270–3.
- Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol [Internet]*. 2020;92(4):418–23.
- Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun [Internet]*. 2020;87:18–22.
- Gabutti G, D’Anchera E, Sandri F, Savio M, Stefanati A. Coronavirus: Update Related to the Current Outbreak of COVID-19. *Infect Dis Ther [Internet]*. 2020;9(2):241–53.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet [Internet]*. 2020; 395(10223):507–13.
- Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. *Lancet [Internet]*. 2020;395(10228):e52.
- Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA [Internet]*. 2020;323(11):1092.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell [Internet]*. 2020;181(2):271–280.e8.
- Sepehrinezhad A, Shahbazi A, Negah SS. COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. *J Neurovirol [Internet]*. 2020;26(3):324–9.
- Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol [Internet]*. 2020 ;92(6):552–5.
- Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci [Internet]*. 2020;11(7):995–8.
- Chan PKS, To K-F, Lo AWI, Cheung JLK, Chu I, Au FWL, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. *J Med Virol [Internet]*. 2004;74(1):1–7.
- Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *J Pathol [Internet]*. 2004;203(2):622–30.
- Gandhi S, Srivastava AK, Ray U, Tripathi PP. Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients? *ACS Chem Neurosci [Internet]*. 2020;11(10):1379–81.17.
- Palasca O, Santos A, Stolte C, Gorodkin J, Jensen LJ. TISSUES 2.0: an integrative web resource on mammalian tissue expression. *Database [Internet]*. 2018 Jan 1;2018. Available from: <https://academic.oup.com/database/article/doi/10.1093/database/bay028/4939216>
- Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis [Internet]*. 2016;213(5):712–22.

19. Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. *Transl Stroke Res* [Internet]. 2020;11(3):322–5.
20. Cetinkaya EA. Coincidence of COVID-19 Infection and Smell. *J Craniofac Surg* [Internet]. 2020 May 6; Publish Ah. Available from: <https://journals.lww.com/10.1097/SCS.00000000000006601>
21. Li Z, Liu T, Yang N, Han D, Mi X, Li Y, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. *Front Med* [Internet]. 2020 May 4; Available from: <http://link.springer.com/10.1007/s11684-020-0786-5>
22. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. *J Clin Neurosci* [Internet]. 2020 May; Available from: <https://linkinghub.elsevier.com/retrieve/pii/S096758682031078X>
23. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun* [Internet]. 2020;88:11–6.
24. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Oto-Rhino-Laryngology* [Internet]. 2020 Apr 6;
25. Zhou Y, Li W, Wang D, Mao L, Jin H, Li Y, et al. Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management. *Stroke Vasc Neurol* [Internet]. 2020;5(2):177–9.
26. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. *Neurology* [Internet]. 2020;95(5):e601–5.
27. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* [Internet]. 2020;77(6):683.
28. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. *Brain Behav Immun* [Internet]. 2020;87:115–9.
29. Al Saiegh F, Ghosh R, Leibold A, Avery MB, Schmidt RF, Theofanis T, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. *J Neurol Neurosurg Psychiatry* [Internet]. 2020;91(8):846–8.
30. Jin H, Hong C, Chen S, Zhou Y, Wang Y, Mao L, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke Vasc Neurol* [Internet]. 2020;5(2):146–51.
31. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res* [Internet]. 2020;21(1):74.
32. Sohal S, Mansur M. COVID-19 Presenting with Seizures. *IDCases* [Internet]. 2020;20:e00782.
33. Lahiri D, Ardila A. COVID-19 Pandemic: A Neurological Perspective. *Cureus* [Internet]. 2020 Apr 29; Available from: <https://www.cureus.com/articles/30897-covid-19-pandemic-a-neurological-perspective>
34. Zanin L, Saraceno G, Panciani PP, Renisi G, Signorini L, Migliorati K, et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. *Acta Neurochir (Wien)* [Internet]. 2020;162(7):1491–4.
35. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis* [Internet]. 2020;94:55–8.
36. Zayet S, Ben Abdallah Y, Royer P-Y, Toko-Tchiundzie L, Gendrin V, Klopfenstein T. Encephalopathy in patients with COVID-19: ‘Causality or coincidence?’ *J Med Virol* [Internet]. 2020;jmv.26027.
37. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* [Internet]. 2020;18(5):1094–9.
38. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. *Cureus* [Internet]. 2020; Available from: <https://www.cureus.com/articles/29414-neurological-complications-of-coronavirus-disease-covid-19-encephalopathy>
39. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* [Internet]. 2020 Mar 26;m1091.
40. Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 COVID -19 and neurodegenerative disorders. *Dermatol Ther* [Internet]. 2020 May 26;
41. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. *ACS Chem Neurosci* [Internet]. 2020 ;11(9):1206–9.
42. Carod Artal FJ. Complicaciones neurológicas por coronavirus y COVID-19. *Rev Neurol* [Internet]. 2020;70(09):311.
43. Shaikh AG, Mitoma H, Manto M. Cerebellar Scholars’ Challenging Time in COVID-19 Pandemia. *The Cerebellum* [Internet]. 2020;19(3):343–4.
44. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. *Laryngoscope* [Internet]. 2020;130(7):1787–1787.
45. Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. *Compr Psychiatry* [Internet]. 2020;100:152184.
46. Cetinkaya EA. Coincidence of COVID-19 Infection and Smell. *J Craniofac Surg* [Internet]. 2020 May 6; Publish Ah. Available from: <https://journals.lww.com/10.1097/SCS.00000000000006601>
47. Ng Kee Kwong KC, Mehta PR, Shukla G, Mehta AR. COVID-19, SARS and MERS: A neurological perspective. *J Clin Neurosci* [Internet]. 2020;77:13–6.
48. Zhai P, Ding Y, Li Y. The impact of COVID-19 on ischemic stroke: A case report. *Res Sq*. 2020;
49. Ferrarese C, Silani V, Priori A, Galimberti S, Agostoni E, Monaco S, et al. An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID). *Neurol Sci* [Internet]. 2020;41(6):1355–9.

50. Rohit B, Padma Srivastava M, Khurana D, Pandit L, Mathew T, Gupta S, et al. Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology. *Ann Indian Acad Neurol* [Internet]. 2020;23(7):5.
51. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. *Clin Neurol Neurosurg* [Internet]. 2020;194:105921.
52. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. *Mult Scler Relat Disord* [Internet]. 2020;42:102163.
53. Schirinzi T, Cerroni R, Di Lazzaro G, Liguori C, Scalise S, Bovenzi R, et al. Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. *Neurol Sci* [Internet]. 2020;41(6):1373–5.
54. Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. *Mov Disord* [Internet]. 2020;35(5):711–5.
55. Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. *Mov Disord Clin Pract* [Internet]. 2020;7(4):361–72.
56. Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities. *J Parkinsons Dis* [Internet]. 2020;10(2):351–4.
57. French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L, et al. Keeping people with epilepsy safe during the COVID-19 pandemic. *Neurology* [Internet]. 2020; 94(23):1032–7.
58. COVID-19 and Epilepsy. 2020; Available from: <https://www.epilepsy.com/learn/covid-19-and-epilepsy>
59. AES STATEMENT ON COVID-19. 2020; Available from: [https://www.aesnet.org/about\\_aes/position\\_statements/covid-19](https://www.aesnet.org/about_aes/position_statements/covid-19)
60. Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. *J Neurol Sci* [Internet]. 2020;412:116803.

